丙型肝炎病毒(HCV)实验性疫苗的研究进展  

Progress in Vaccine Development of Hepatitis C Virus

作　　者：谭文杰[1] 张柯[1] 阮力[1] 

机构地区：[1]中国疾病预防控制中心病毒病预防控制所,北京100052

出　　处：《中国生物工程杂志》2006年第10期64-70,共7页China Biotechnology

基　　金：国家自然科学基金资助项目(30571673)

摘　　要：丙型肝炎病毒是引起输血相关肝炎及慢性肝炎、肝硬化、肝癌的主要病原,目前尚无有效的治疗与预防手段。综述了HCV感染所引起的机体免疫应答及近年来实验性疫苗(主要是DNA疫苗、病毒载体疫苗及联合疫苗)的研究进展及面临的挑战,并提出,激发广谱、强大T细胞应答的初免-加强免疫方案是HCV实验性疫苗研制的新策略。Hepatitis C virus （HCV） accounts for the majority of cases of transfusion acquired hepatitis and may cause chronic hepatitis, cirrhosis and hepatocellular carcinoma. Currently, there is no vaccine against HCV and treatment is expensive and not always effective. The adaptive host immune response in viral clearance of HCV infection was described and the recent progress in vaccine development of HCV, focusing on the fields of DNA vaccine candidates, recombinant viral vectored vaccine candidates and combined （prime-boost） vaccine candidates were summarized. Some challenges and limitations of developing a HCV vaccine were also analysed. In summary, a promising approach of developing an experimental HCV vaccine to induce extremely potent and broad T-cell responses based on prime-boost strategy was presented.

关 键 词：丙型肝炎病毒 DNA疫苗病 毒载体疫苗 初免-加强免疫策略 

分 类 号：Q819[生物学—生物工程]